CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

被引：18

作者：

Bhatt, Geetika ^{[1
]}

Maddocks, Kami ^{[1
]}

Christian, Beth ^{[1
]}

机构：

[1] Ohio State Univ, James Comprehens Canc Ctr, 420 West 10th Ave,A348 Starling Loving Hall, Columbus, OH 43210 USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2016年 / 11卷 / 06期

关键词：

Hodgkin lymphoma; Non-Hodgkin lymphoma; Antibody-drug conjugate; Brentuximab vedotin; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANTI-CD30; ANTIBODY; 5F11; ACUTE MYELOID-LEUKEMIA; BRENTUXIMAB VEDOTIN; ANTITUMOR-ACTIVITY; PHASE-II; RECEPTOR FAMILY; ANTIGEN KI-1; OPEN-LABEL; HIGH-RISK;

D O I：

10.1007/s11899-016-0345-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Evolution of cancer therapeutics has resulted in the development of agents with varying mechanisms of selective target inhibition. One such therapeutic approach is utilizing antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic agent in order to maximize efficacy with fewer toxicities. This review focuses on CD30 as a therapeutic target and the development and clinical activity of the ADC brentuximab vedotin in Hodgkin lymphoma (HL) and other B cell lymphomas.

引用

页码：480 / 491

页数：12

共 88 条

[1] Site-Specific Antibody-Drug Conjugates: The Nexus of Biciorthogonal Chemistry, Protein Engineering, and Drug Development [J].

Agarwal, Paresh ;

Bertozzi, Carolyn R. .

BIOCONJUGATE CHEMISTRY, 2015, 26 (02) :176-192

[2]

[Anonymous], J CLIN ONCOL S

[3]